
GLP-1 Weight Loss Drugs: The Risk of Stopping and Restarting
New research suggests that the effectiveness of popular GLP-1 weight loss medications may significantly diminish with intermittent use. Understand the implications for your health journey.
The Shotlee Journal
Browse Shotlee articles about Weight Loss.
Showing 9 / 1248 Weight Loss articles

New research suggests that the effectiveness of popular GLP-1 weight loss medications may significantly diminish with intermittent use. Understand the implications for your health journey.

The U.S. Food and Drug Administration (FDA) has proposed a significant change that could reshape the landscape of weight-loss drug accessibility. By suggesting the exclusion of key active ingredients from the list of drugs that outsourcing facilities can compound in bulk, the FDA aims to curb large-scale, unauthorized production of popular medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).

What began as a treatment for diabetes has rapidly evolved into a powerful force reshaping consumer behavior and Canada's agri-food economy. GLP-1 drugs are no longer niche medical interventions; they are becoming mainstream, driving significant changes in how Canadians eat and shop.

The rise of GLP-1 medications like Ozempic and Mounjaro has brought significant advancements in weight management and diabetes care. However, as more individuals embrace these therapies, understanding and managing potential side effects becomes crucial for a successful health journey.

The rise of GLP-1 medications for weight loss has brought to light a common side effect: temporary hair thinning. This article delves into why this happens and what you can do about it.

Plus-size model Ashley Graham expresses her disappointment and concern over the increasing popularity of GLP-1 weight loss drugs, viewing it as a setback for body acceptance movements.

The traditional concept of retirement is being redefined as men in midlife increasingly focus on maintaining vitality and appearance, extending their 'hotspan' well into later years.

A recent study published in JAMA Psychiatry has unveiled promising findings regarding GLP-1 receptor agonists, such as semaglutide, and their potential to address a core symptom of major depressive disorder: a lack of motivation. This article delves into the study's methodology, results, and the broader implications for mental health treatment.

GLP-1 agonists are revolutionizing weight management, but their effects extend far beyond the scale. This article delves into the science, the side effects like 'Ozempic breath,' and how these powerful medications are reshaping consumer habits and personal health journeys.